Structure and Function of Fcε Receptor II (FcεRII/CD23): A Point of Contact Between the Effector Phase of Allergy and B Cell Differentiation

  1. Derek J. Chadwick Organizer,
  2. David Evered Organizer and
  3. Julie Whelan
  1. Hitoshi Kikutani,
  2. Akira Yokota,
  3. Naoto Uchibayashi,
  4. Kazunori Yukawa,
  5. Tetsuji Tanaka,
  6. Kenji Sugiyama,
  7. Edward L. Barsumian,
  8. Masaki Suemura and
  9. Tadamitsu Kishimoto

Published Online: 28 SEP 2007

DOI: 10.1002/9780470513866.ch3

Ciba Foundation Symposium 147 - IgE, Mast Cells and the Allergic Response

Ciba Foundation Symposium 147 - IgE, Mast Cells and the Allergic Response

How to Cite

Kikutani, H., Yokota, A., Uchibayashi, N., Yukawa, K., Tanaka, T., Sugiyama, K., Barsumian, E. L., Suemura, M. and Kishimoto, T. (2007) Structure and Function of Fcε Receptor II (FcεRII/CD23): A Point of Contact Between the Effector Phase of Allergy and B Cell Differentiation, in Ciba Foundation Symposium 147 - IgE, Mast Cells and the Allergic Response (eds D. J. Chadwick, D. Evered and J. Whelan), John Wiley & Sons, Ltd., Chichester, UK. doi: 10.1002/9780470513866.ch3

Author Information

  1. Division of Immunology, Institute for Molecular and Cellular Biology, Osaka University, 1-3, Yamada-oka, Suita, Osaka 565, Japan

Publication History

  1. Published Online: 28 SEP 2007

ISBN Information

Print ISBN: 9780471923091

Online ISBN: 9780470513866

SEARCH

Keywords:

  • B cell differentiation;
  • IgE-mediated immunity;
  • cDNA transfection;
  • monoclonal antibodies;
  • transformants

Summary

The Fcε receptor II (FcεRII/CD23) has been proposed to have multiple functions as a membrane-bound or soluble molecule: a function in B cell growth and differentiation and a role in the effector phase of IgE-mediated immunity. We recently demonstrated the presence of two forms of FcεRII (FcεRIIa and FcεRIIb) whose structures differ only at their N-terminal cytoplasmic regions. The regulatory mechanisms of their expression strongly suggest that FcεRIIa and FcεRIIb function in B cells and in the effector cells of IgE-mediated immunity, respectively. To elucidate the function of soluble FcεRII/CD23 (sFcεRII) the recombinant soluble molecule was produced. This recombinant receptor could competitively block the IgE binding of eosinophils, monocytes and even basophils and could inhibit the IgE-mediated function of effector cells such as monocytes. These findings suggested that sFcεRII could competitively regulate the function of effector cells in IgE-mediated immunity and that the recombinant sFcεRII could be applied clinically for the control of allergic reactions. The expression of FcεRII on FcεRII-negative B and T cell lines by cDNA transfection resulted in homocytic aggregation. The function of FcεRII on B cells as an adhesion molecule was also demonstrated.